InMed Pharmaceuticals (INM) Depreciation and Depletion (2019 - 2023)

InMed Pharmaceuticals has reported Depreciation and Depletion for 5 years, with the latest figure at $13839.0 in Q3 2023.

• On a quarterly basis, Depreciation and Depletion rose 71.81% year-over-year to $13839.0 in Q3 2023; TTM through Sep 2023 was $45397.0, a 50.0% increase from a year earlier, with the FY2023 full-year figure at $39613.0, up 49.9% from the prior year.
• Depreciation and Depletion was $13839.0 for Q3 2023 at InMed Pharmaceuticals, up from $12916.0 in the prior quarter.
• The five-year high for Depreciation and Depletion was $27795.0 in Q4 2019, with the low at $3633.0 in Q1 2021.
• Average Depreciation and Depletion over 5 years is $10792.0, with a median of $8055.0 recorded in 2022.
• The sharpest annual moves came in 2021 and 2022: Depreciation and Depletion tumbled 86.48% in 2021, then soared 117.67% in 2022.
• Over 5 years, Depreciation and Depletion stood at $27795.0 in 2019, then sank by 76.51% to $6528.0 in 2020, then slipped by 4.32% to $6246.0 in 2021, then grew by 28.98% to $8056.0 in 2022, then soared by 71.79% to $13839.0 in 2023.
• The last three Depreciation and Depletion figures came in at $13839.0 (Q3 2023), $12916.0 (Q2 2023), and $10586.0 (Q1 2023), per Business Quant data.